Event-Driven Stocks

Revance Therapeutics, Inc.

RVNC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 4 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY23FY22FY21FY20FY19FY18
Revenue$234.0M$132.6M$77.8M$15.3M$413,000$3.7M
Operating income−$316.8M−$342.0M−$274.7M−$273.2M−$164.5M−$142.6M
Net income−$324.0M−$356.4M−$281.3M−$282.1M−$159.4M−$142.6M
Total assets$478.5M$581.9M$531.2M$720.2M$340.3M$226.3M
Total liabilities$630.1M$569.3M$462.7M$345.9M$114.8M$80.7M
Equity−$151.6M$12.6M$68.5M$374.3M$225.5M$145.6M
EPS (diluted)$-3.83$-4.90$-4.17$-4.86$-3.67—
Shares out.82.8M71.5M71.4M56.9M44.0M36.7M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2023
Operating margin
−135.4%
Net margin
−138.4%
Return on equity
213.7%
Return on assets
−67.7%
Return on capital (ROCE)
−81.4%
Liabilities / assets
131.7%
Debt / equity
—
Book value / share
$-1.83
Revenue growth (YoY)
76.5%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2023
Altman Z″ (distress)
-15.44distress
Accruals / assets
−22.4%clean
Piotroski F-Score
3/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
56
/ 100
Profitability 20Growth 100Catalyst 67Earnings quality 67Financial strength 25

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 4 warning● 3 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)